DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the stock.

Other analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of DBV Technologies in a research report on Thursday, August 1st. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price target on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Trading Up 1.6 %

NASDAQ:DBVT opened at $0.70 on Friday. DBV Technologies has a twelve month low of $0.50 and a twelve month high of $2.74. The firm has a market capitalization of $67.15 million, a price-to-earnings ratio of -0.83 and a beta of 0.68. The firm’s fifty day simple moving average is $0.86 and its 200 day simple moving average is $1.07.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. During the same period in the previous year, the company earned ($0.26) EPS. On average, analysts predict that DBV Technologies will post -1.43 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. increased its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the period. DBV Technologies comprises about 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.